Evidence map›Paper›PMID 39256358›Full record

ReviewTranslational psychiatry2024

MicroRNAs: pioneering regulators in Alzheimer's disease pathogenesis, diagnosis, and therapy.

Yao-Bo Li, Qiang Fu, Mei Guo, Yang Du, Yuewen Chen, Yong Cheng

Abstract readReview
In one paragraph

Review in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. International journal of molecular sciences · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yao-Bo LiCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
Qiang FuInstitute of National Security, Minzu University of China, Beijing, China.
Mei GuoKey Laboratory of Ethnomedicine of Ministry of Education, School of Pharmacy, Minzu University of China, Beijing, China.
Yang DuInstitute of National Security, Minzu University of China, Beijing, China.
Yuewen ChenChinese Academy of Sciences Key Laboratory of Brain Connectome and Manipulation, Shenzhen Key Laboratory of Translational Research for Brain Diseases, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China. yw.chen1@siat.ac.cn.
Yong ChengCenter on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China. yongcheng@muc.edu.cn.ORCID 0000-0002-7529-4408

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82071676
6 · The paper itself

Abstract

This article delves into Alzheimer's disease (AD), a prevalent neurodegenerative condition primarily affecting the elderly. It is characterized by progressive memory and cognitive impairments, severely disrupting daily life. Recent research highlights the potential involvement of microRNAs in the pathogenesis of AD. MicroRNAs (MiRNAs), short non-coding RNAs comprising 20-24 nucleotides, significantly influence gene regulation by hindering translation or promoting degradation of target genes. This review explores the role of specific miRNAs in AD progression, focusing on their impact on β-amyloid (Aβ) peptide accumulation, intracellular aggregation of hyperphosphorylated tau proteins, mitochondrial dysfunction, neuroinflammation, oxidative stress, and the expression of the APOE4 gene. Our insights contribute to understanding AD's pathology, offering new avenues for identifying diagnostic markers and developing novel therapeutic targets.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesMicroRNAsOxidative Stresstau ProteinsAnimalsApolipoprotein E4Gene Expression RegulationHumansAmyloid beta-PeptidesApolipoprotein E4MicroRNAstau Proteins

Identifiers

PMID39256358
PMCPMC11387755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.